Nusano (West Valley City, UT) achieved its first accelerator commissioning milestone, validating core LINAC systems and advancing its West Valley City platform toward commercial radioisotope production by the end of 2026.
West Valley City, Utah — June 25, 2026
Less than a year after opening its $300 million West Valley City production campus, Nusano has reached a key technical milestone on the path to commercial radioisotope production.
The company announced it has successfully accelerated particles from its proprietary ion source through the low-energy beam transport (LEBT) and radiofrequency quadrupole (RFQ) sections of its linear accelerator (LINAC) to a target, a demonstration known internally as "Beam on Target."
When TechBuzz covered the opening of the West Valley facility, company leaders described the proprietary accelerator as the centerpiece of Nusano's strategy to expand the supply of medical radioisotopes. This latest demonstration represents the first successful commissioning of that system, validating its ability to generate, shape and deliver a particle beam to a defined endpoint.
During the test, particles reached approximately 28 percent of the platform's planned full operating energy, confirming the performance of the LINAC's front-end systems. The milestone is the first of three commissioning phases leading to full operation, which the company expects by the end of 2026.
Two major demonstrations remain on the schedule. In September, Nusano plans to send a beam through the complete linear accelerator to a target, demonstrating initial radioisotope production capability. A final validation is planned for December, when steering magnets will direct accelerated particles into a production target bay, completing a full demonstration of the commercial production platform.
The milestone advances the vision Nusano outlined when it opened the West Valley campus: creating a domestic source of radioisotopes to address persistent supply shortages that continue to limit diagnostic imaging and targeted cancer therapies. At full capacity, the company expects the platform to produce more than 40 radioisotopes and as many as 12 different isotopes simultaneously.
For Nusano, "Beam on Target" is more than a successful accelerator test. It marks the transition from building the infrastructure to commissioning the technology that will ultimately power commercial-scale radioisotope production. If the remaining demonstrations proceed as planned, the company will bring one of the nation's most advanced isotope production platforms online before the end of next year.
For more information about Nusano's technology, visit Nusano's website. View demonstration of "beam-on-target" below: